Vivos Therapeutics Change in Accounts Payable 2020-2025 | VVOS

Vivos Therapeutics change in accounts payable from 2020 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.

Vivos Therapeutics Change in Accounts Payable 2020-2025 | VVOS

Vivos Therapeutics change in accounts payable from 2020 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$69.6B
Zoetis (ZTS)$69B
Takeda Pharmaceutical (TAK)$48.7B
Daiichi Sankyo, - (DSNKY)$47.9B
BeOne Medicines - (ONC)$34.4B
Sandoz Group AG (SDZNY)$26.7B
Summit Therapeutics (SMMT)$19.3B
Merck (MKKGY)$16.7B
Shionogi (SGIOY)$14.9B
United Therapeutics (UTHR)$14B
Neurocrine Biosciences (NBIX)$13.4B
IPSEN (IPSEY)$11.3B
Orion OYJ (ORINY)$11.2B
Eisai (ESAIY)$9.1B
Madrigal Pharmaceuticals (MDGL)$9B
Corcept Therapeutics (CORT)$7.5B
Grifols, S.A (GRFS)$6.9B
Stevanato Group S.p.A (STVN)$6.9B
Ionis Pharmaceuticals (IONS)$6.9B
Ono Pharmaceutical (OPHLF)$5.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.4B
Soleno Therapeutics (SLNO)$3.7B
Procaps Group, S.A (PROCF)$3.2B
AMNEAL PHARMACEUTICALS, INC (AMRX)$3B
Crinetics Pharmaceuticals (CRNX)$2.8B
NewAmsterdam Pharma (NAMS)$2.8B
Hypermarcas (HYPMY)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.3B
Ocular Therapeutix (OCUL)$2.1B